Altimunne (ALT)

Altimmune, Inc (ALT) CEO Bill Enright on Q2 2018 Results - Earnings Call Transcript
Aug. 15, 2018 | Price: Free! | Source: Seeking Alpha

PharmAthene's CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 12, 2014 | Price: Free! | Source: Seeking Alpha

PharmAthene Management Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc - Q2 2013 Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Earnings Impact

PharmAthene, Inc. Q2 2013 Earnings Conference Call Transcript
Aug. 7, 2013 | Price: $106.00 | Source: Thomson

PharmAthene, Inc., Theraclone Sciences, Inc. - M&A Call
Aug. 1, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics
Aug. 1, 2013 | Price: $106.00 | Source: Thomson

PharmAthene Management Discusses Q1 2013 Results - Earnings Call Transcript
May 8, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. Q1 2013 Earnings Conference Call Transcript
May 8, 2013 | Price: $54.00 | Source: Thomson

PharmAthene, Inc. Q4 2012 Earnings Conference Call Transcript
March 13, 2013 | Price: $106.00 | Source: Thomson

PharmAthene Management Discusses Q4 2012 Results - Earnings Call Transcript
March 13, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene Management Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 6, 2012 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. Q3 2012 Earnings Conference Call Transcript
Nov. 6, 2012 | Price: $54.00 | Source: Thomson

PharmAthene, Inc. Q1 2012 Earnings Conference Call Transcript
May 8, 2012 | Price: $54.00 | Source: Thomson

Recent filings

Altimunne: Altimmune Launches Clinical Trial Of T-COVID - June 1, 2020

Koh, Bong just provided an update on share ownership of Altimunne - June 1, 2020

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - June 1, 2020

Major owner of Altimunne just picked up 1,303,636 shares - May 28, 2020

Major owner of Altimunne just declared owning 1,696,364 shares of Altimunne - May 28, 2020

Major owner of Altimunne just disposed of 200,000 shares - May 18, 2020

Altimunne Just Filed Its Quarterly Report: 4.Net Loss Per Share... - May 13, 2020

Altimunne: Altimmune Announces First Quarter 2020 Financial Results And Provides A Business Update - May 13, 2020

Altimunne director was just granted 40,000 options - May 12, 2020

Altimunne: Altimmune Appoints Former Pfizer And Gsk Executive Diane Jorkasky, M.D. To Its Board Of Directors GAITHERSBURG, Maryland, May - May 12, 2020

Altimunne director just declared ownership of no shares of Altimunne - May 12, 2020

Altimunne's President and CEO just disposed of 2,015 shares - May 4, 2020

Entry into a Material Definitive - April 8, 2020

Altimunne's President and CEO just disposed of 2,016 shares - April 1, 2020

Altimunne Just Filed Its Annual Report: 4. Net Loss Per... - March 27, 2020

Entry into a Material Definitive - March 27, 2020

Altimunne: Altimmune Announces Financial Results For The Year Ended December 31, 2019 And Provides A Corporate Update - March 27, 2020

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - March 27, 2020

Altimunne's President and CEO just disposed of 2,015 shares - March 3, 2020

James Watson just provided an update on share ownership of Altimunne - Feb. 14, 2020

Major owner of Altimunne just declared owning 1,887,250 shares of Altimunne - Feb. 14, 2020

Statement of acquisition of beneficial ownership by individuals - Feb. 11, 2020

Altimunne's Chief Scientific Officer just picked up 3,698 shares - Feb. 4, 2020

Altimunne's Chief Financial Officer just picked up 8,061 shares - Feb. 4, 2020

Altimunne's President and CEO just picked up 11,289 shares - Feb. 4, 2020

Altimunne's President and CEO just disposed of 2,015 shares - Feb. 3, 2020

Sander Gerber just provided an update on share ownership of Altimunne - Jan. 31, 2020

Altimunne's Chief Financial Officer was just granted 61,400 options - Jan. 3, 2020

Altimunne's Chief Medical Officer was just granted 61,400 options - Jan. 3, 2020

Altimunne's President and CEO was just granted 149,500 options - Jan. 3, 2020

Altimunne's Chief Scientific Officer was just granted 61,400 options - Jan. 3, 2020

Altimunne's President and CEO just disposed of 1,999 shares - Jan. 2, 2020

Altimunne's President and CEO just disposed of 23,976 shares - Dec. 3, 2019

Altimunne: Altimmune Announces Third Quarter 2019 Financial Results And Provides A Business Update - Nov. 13, 2019

Altimunne Just Filed Its Quarterly Report: 4.Net Loss Per Share... - Nov. 13, 2019

Departure of Directors or Certain - Oct. 1, 2019

Altimunne's Chief Medical Officer was just granted 107,000 options - Sept. 11, 2019

Altimunne's Chief Medical Officer just declared ownership of no shares of Altimunne - Sept. 11, 2019

Altimunne's President and CEO just picked up 20,000 shares - Sept. 5, 2019

Other definitive proxy statements - Aug. 22, 2019

Altimunne: Altimmune Announces $3.7 Million In Additional Barda Funding To Advance Nasoshield Clinical Development - Aug. 21, 2019

Preliminary Proxy Soliciting materials - Aug. 19, 2019

Securities to be offered to employees in employee benefit plans - Aug. 14, 2019

Altimunne Just Filed Its Quarterly Report: 4.Net Loss Per Share... - Aug. 13, 2019

Altimunne: Results Of Operations And Financial Condition - Aug. 13, 2019

Other preliminary proxy statements - Aug. 9, 2019

Altimunne: Altimmune Announces Closing Of Acquisition Of Spitfire Pharma, Inc - July 15, 2019

Altimunne: Altimmune Signs Definitive Agreement To Acquire Spitfire Pharma, Inc. Adding Nash Drug Candidate To Portfolio - July 9, 2019

Departure of Directors or Certain - June 21, 2019

Altimunne's Chief Medical Officer was just granted 20,000 options - June 19, 2019

Altimunne: Altimmune Appoints Will Brown As Chief Financial Officer GAITHERSBURG, Maryland, June - June 12, 2019

Altimunne's Chief Financial Officer was just granted 50,000 options - June 12, 2019

Departure of Directors or Certain - June 7, 2019

Altimunne: Altimmune Announces First Quarter 2019 Financial Results And Provides A Business Update - May 14, 2019

Altimunne Just Filed Its Quarterly Report: 3.Net Loss Per Share... - May 14, 2019

Altimunne Just Received a Notice of Effectiveness - April 12, 2019

Registration statement under Securities Act of 1933 - April 4, 2019

Securities to be offered to employees in employee benefit plans - April 4, 2019

Altimunne Just Filed Its Annual Report: 4. Net Loss Per... - April 1, 2019

Altimunne: Altimmune Announces Financial Results For The Year Ended December 31, 2018 And Provides Corporate Update - April 1, 2019

Altimunne's Chief Scientific Officer was just granted 38,000 options - March 27, 2019

Altimunne's Chief Medical Officer was just granted 38,000 options - March 27, 2019

Departure of Directors or Certain - March 15, 2019

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - March 11, 2019

Altimunne: Altimmune Announces $14 Million Registered Direct Offering - March 11, 2019

Altimunne: Altimmune Announces Clinical Program Updates And Plans For Pipeline Expansion - March 8, 2019

OFCO Club V just provided an update on share ownership of Altimunne - Feb. 11, 2019

Intracoastal Capital LLC just provided an update on share ownership of Altimunne - Feb. 8, 2019

Novartis AG just provided an update on share ownership of Altimunne - Feb. 5, 2019

Sander Gerber just provided an update on share ownership of Altimunne - Feb. 1, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's Acting Chief Financial Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's Chief Medical Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's Chief Scientific Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's President and CEO just declared ownership of no shares of Altimunne - Dec. 4, 2018

Departure of Directors or Certain - Dec. 3, 2018

Summary Consolidated Financial Data - Nov. 30, 2018

Departure of Directors or Certain - Oct. 22, 2018

Statement of acquisition of beneficial ownership by individuals - Oct. 17, 2018

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - Oct. 9, 2018

Heights Capital Management, Inc. just provided an update on share ownership of Altimunne - Oct. 5, 2018

Major owner of Altimunne just declared ownership of no shares of Altimunne - Oct. 4, 2018

Novartis AG just provided an update on share ownership of Altimunne - Oct. 4, 2018

Confidential treatment order - Oct. 4, 2018

Post-effective amendment adding exhibits to registration statement [Rule 462(d)] - Sept. 28, 2018

Altimunne Just Received a Notice of Effectiveness - Sept. 27, 2018

General form for registration of securities under the Securities Act of 1933 - Sept. 26, 2018

Altimunne: Altimmune Announces $4.9 Million Registered Direct Offering Of Common Stock GAITHERSBURG, MD, September - Sept. 25, 2018

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - Sept. 24, 2018

Altimunne: Altimmune Awarded $2.5 Million In Additional Barda Funding To Support - Sept. 24, 2018

Major owner of Altimunne just picked up 2,069,993 shares - Sept. 14, 2018

Amendments to Article of Incorporation or - Sept. 13, 2018

The Companys stockholders had previously approved a reverse split ratio of not less than - Sept. 12, 2018

Altimunne director just declared ownership of no shares of Altimunne - Sept. 10, 2018

Altimunne: Altimmune Announces Additional Positive Data From Its Phase 2A Study - Sept. 4, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. BlackRock Fund Advisors 1,714,857 N/A Sept. 30, 2016
2. Potomac Capital Management, Inc. 591,134 0.7 Sept. 30, 2015
3. GRUBER & MCBAINE CAPITAL MANAGEMENT LLC 572,950 N/A March 31, 2015
4. BlackRock Institutional Trust Company, N.A. 485,324 N/A Dec. 31, 2016
5. MORGAN STANLEY 234,175 N/A Dec. 31, 2016
6. BlackRock Investment Management, LLC 233,794 N/A Dec. 31, 2016
7. BlackRock Advisors LLC 36,673 N/A Sept. 30, 2016
8. BlackRock Inc. 3,427 N/A Sept. 30, 2016
9. MetLife Securities, Inc 100 N/A Dec. 31, 2016
10. Kurt Wheeler 0 N/A March 24, 2016

Altimunne (ALT)

140
 


Feedback